Phase 2 RCT | A single injection of a monoclonal antibody was 88% effective for malaria prevention over 6 months.
2 Nov, 2022 | 14:30h | UTCSafety and Efficacy of a Monoclonal Antibody against Malaria in Mali – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Monoclonal antibody prevents malaria infection in African adults – National Institutes of Health
Commentary: Monoclonal antibody infusion 88% effective against malaria – CIDRAP
Related Study: Phase 1 Study | Low-dose subcutaneous or intravenous monoclonal antibody can prevent malaria in a human challenge model.
Commentary on Twitter
In this phase 2 trial in Mali, an antimalarial monoclonal antibody (CIS43LS) at the higher dose (40 mg per kilogram) was approximately 88% effective at preventing P. falciparum infection as compared with placebo. #TropMed22 https://t.co/UGeBHOPhKY pic.twitter.com/uFX7w3qV0G
— NEJM (@NEJM) November 1, 2022